CDK4 and neoplasm: We observed that PDX KCC_P_3837-FPR mice treated with the triple combination showed a statistically significant (p = 0.003) increase in progression-free survival (PFS), with progression defined as tumor width ≥ 5 mm, compared to mice in the combined CDK4/6i and fulvestrant treatment group (Fig. 6D).